18F-fluorodeoxyglucose PET/CT as a metabolic alternative to biopsy in a gastrointestinal stromal tumor?
S. Balogová(1, 2), D. Viglietti(2), A.M. Tardivel(2), L. Kaliská(3), M. Vereb(4), M. Bartovic(1), D. Cích)1, V. Pročka(1), Ľ. Lukáč(5)
1 Klinika nukleárnej medicíny LF UK a OÚSA, Bratislava
2 Klinika nukleárnej medicíny nemocnice Tenon AP-HP & Université Pierre et Marie Curie, Paríž, Francúzsko
3 Inštitút nukleárnej a molekulárnej medicíny Košice, pracovisko Banská Bystrica, Agel diagnostics s.r.o.
4 Oddelenie nukleárnej medicíny Reimanus s.r.o., Prešov
5 I. Interná klinika LF UK a UNB, Bratislava
The usefulness of fludeoxyglucose-(18F) (FDG) PET/CT in different clinical settings of many malignancies is well documented. Early evaluation of therapeutic response by means of functional imaging providing important predictive and prognostic information is particularly interesting. Furthermore, certain anticancer agents show significant therapeutic specificity for certain types of malignancies and therapeutic test evaluated by functional imaging may serve as metabolic surrogate for histology (“metabolic biopsy”). Gastrointestinal stromal tumours are FDG avid mesenchymal tumours, in most cases well responding to treatment by thyrosine-kinase inhibitors (imatinib mesylate, sunitinib maleate). Therapeutic test by imatinib mesylate evaluated by FDG PET/CT may potentially serve as “metabolic biopsy” in patients presenting tumour evocative of GIST. This article illustrates the potential role of “metabolicbiopsy” in routine management of patients with abdominal tumour evocative of GIST.
